CardieX Limited (ASX: CDX) is working in the space of health technology at the global level. It aims to provide health solutions for large scale population through digital and device-based solutions. The company has developed a product named XCEL which measures the central blood pressure which is considered to be essential for various cardiovascular disorders. It has also entered a joint venture with Blumio Inc. for the development of a radar-based blood pressure sensor.
On 2nd April 2019, the company announced that its group company inHealth Medical Services, Inc (inHealth) is conducting a new ground-breaking study and collaboration on cardiovascular disease and telehealth by utilising subsidiary AtCor Medical’s innovative SphygmoCor® technology.
inHealth is a provider of Telehealth services in the US which helps the patients to connect online with their respective health coaches by providing e-commerce, digital and mobile tools to them as a part of patient care program. These patient care programs are a long-term clinical trial that exhibits superior patient outcomes using Telehealth coaching services. It is also in partnerships with many healthcare institutions in the USA like Kaiser Permanente, Anthem etc.
In the process of carrying out the study, inHealth has secured two highly coveted research collaborators. One is the Pennington Biomedical Research Center at Louisiana State University which is the largest obesity research center in the US and the other is leading research mHealth center, The University of South Carolina.
The collaborators will also support inHealth’s diabetes lifestyle intervention study which exhibits the clinical importance of telehealth services in the management of chronic disease.
inHealth is currently undertaking one of the broadest lifestyle intervention studies to date in partnership with Kaiser Permanente, together with California State University Long Beach (CSULB) which aims to establish effects of lifestyle intervention and telehealth coaching on disease progression, treatment and, management.
iHealth’s cardiovascular study will be the first study in the world to investigate how cost-effective telehealth solutions can prevent and improve cardiovascular disease. Globally, cardiovascular disease is the top cause of premature death for which the cost of treatment is expected to exceed $1 trillion by 2035.
This trial will utilise AtCor’s SphygmoCor technology which is used clinically for central arterial pressure waveform analysis to better inform blood pressure treatment options. This analysis provides clinicians with better prognostic and diagnostic information to determine the need for and type of intervention which cannot be detected with standard blood pressure measurement.
The company is also engaged in diabetes lifestyle intervention study to reduce body weight and support diabetes management. This is a seven years study which uses exercise, lifestyle telehealth coaching programs and inHealth’s telehealth nutrition. The data, findings and information from the study will be used to further refine and validate inHealth’s existing healthcare programs.
On 1st April 2019, the company provided interim corporate update.
On 6th March 2019, the company announced extension of Atcor’s Medical pharma contract.
On 4th February 2019, the company reported clinical validation of Atcor Medical’s SphygmoCor technology.
The stock of the company closed 2.5% lower at A$0.039 as of 2nd April 2019. In the past three months, the stock has given a rally of 33.3%.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.